1 / 44

GI-NEUROENDOCRINE TUMORS: THERAPEUTIC APPROACHES: SYMPTOMATIC MANAGEMENT

Learn about different therapeutic approaches and symptomatic management strategies for neuroendocrine tumors, including common symptoms, diagnosis methods, and treatment options. Explore long-term survival strategies and the importance of a multidisciplinary approach in patient care.

achavez
Download Presentation

GI-NEUROENDOCRINE TUMORS: THERAPEUTIC APPROACHES: SYMPTOMATIC MANAGEMENT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NET MASTERCLASS 5-7-2014 GI-NEUROENDOCRINE TUMORS: THERAPEUTIC APPROACHES:SYMPTOMATIC MANAGEMENT IOANNIS PILPILIDIS, MD, FEBGH GASTROENTEROLOGY – ONCOLOGYDEPT “THEAGENEIO” CANCER HOSPITAL OF THESSALONIKI

  2. Long – term survival: A chronic disease Yao, JCO 2008; 26: 3063-3072

  3. < 10 ή > 10

  4. Common symptoms are not typical

  5. Typical symptoms are not common

  6. Diagnosis according to the primary Appediceal (8) 100% surgery Upper GI track (duodenal) (31) 100% endoscopy (anemia, dyspepsia) SI (18) 10% incidentaloma 15% liver biopsy 60% obstructive symptoms 15% diarrhea – flushing P-NET (9) 20% hypoglycemia (2) 10% jaundice (1) 40% pain (4) 10% rash (1) 10% weight loss (1) Colon – rectal (4) 25% colon – abdominal pain 75% rectal - incidentaloma

  7. 3.000 years of misdiagnosis God’s help!!! ΜΕΝ I Pituitary tumor Hyperparathyroidism Insulnoma Gene’s help!!! MENIN GENE: 11q13

  8. Liver mets • Peritoneal disease/ retroperitoneal involvement • ovary/testicular

  9. TREATMENT DOES NOT NEED A DIAGNOSIS

  10. Symptoms presentation - • Functionality/hormone activity • carcinoid syndrome • gastrin, insulin, etc • paraneoplastic syndromes • Location of primary • SI (peritoneal fibrosis, heart disease, etc) • p-NET • Tumor stage (tumor load, liver mets etc)

  11. Symptoms presentation • Functionality/hormone activity • deal with symptoms even if no effective tumor treatment • Location of primary • Tumor stage (tumor load, liver mets etc)

  12. Differential diagnosis: Diarrhea: hormone secretion bile acids bacterial overgrowth short bowel syndrome intestinal bypass pancreatic insufficiency (SSAs treatment) Hypoglycemia: insulinoma ? IGF-1, pro-IGF2 Hypergastrinemia: PTH ? (secondary hyperPTH) HyperPTH: Gastrinoma ? (gastrin secretion)

  13. Carcinoid syndrome: response to somatostatin analogues Clinical response 70-90% Biological response35-75% Objective response 0-5%

  14. Symptoms presentation • Functionality/hormone activity • Location of primary • deal with complications • Tumor stage (tumor load, liver mets etc)

  15. Patient selection bias?

  16. Median Survival: 8.5y Median Survival (non cytoreduction): 7.9y vs 11.5y 5-y Survival 75%

  17. In the absence of other data, the resection of the primarytumour only for patients with PNETs and unresectablemetastatic liver disease should only be considered in high-volume referral centres, with strict selection criteriaand in a multidisciplinary setting of patients’ care

  18. Symptoms presentation • Functionality/hormone activity • Location of primary • Tumor stage (tumor load, liver mets etc) • cytoreduction

  19. TACE/TAE: Symptom Control Clinical response: 67% - 100% Biological response: 46% - 91% Ruszniewski Cancer 1993, TherasseRadiol 1993, Tomassetti 1994, Diaco Am J Surg 1995, RuszniewskiEur J GastroenterolHepatol 2000, Roche Hepatogastroenterol 2004, Ruszniewski 2007 PRRT: Symptom Control Global Health QoL = 36% Fatigue = 49% Nause – Vomiting = 70% Pain = 53% Dyspnoea = 44% Insomnia = 59% Appetite loss = 63% Constipation = 60% Diarrhoea = 67%

  20. CLARINET PROMID

  21. Diarrhea: (serotonin secretion, bacterial overgrowth - bypasses): medical treatment Pain: (tumor load)liver directed therapies (TAE/PRRT) Weight loss: (cachexia) tumor control (TAE/PRRT) Pain: (mesenterial/ retroperitoneal fibrosis – ischemia): surgical intervention Weight loss: (undernutrition) surgical intervention MULTIDISCIPLINARY APPROACH

More Related